Anthera saw its shares tank after hours as the biotech announced yet another failed study, this time for its late-stage trial for a GI candidate in cystic fibrosis patients. Its med, known as Sollpura ...

Anthera Pharmaceuticals (ANTH) became the second biotech to make it out the current IPO window and the second biotech to take a haircut on its price -- but that might not be as bad as it sounds.

Anthera Pharmaceuticals, Inc. ANTH announced positive top-line data from the extension of a phase II BRIGHT-SC study, evaluating key pipeline candidate, blisibimod for treatment of patients with IgA ...

NEW YORK (AP) -- Shares of Anthera Pharmaceuticals Inc. skidded Monday after the company stopped a late-stage clinical trial of its cardiovascular disease drug varespladib. THE SPARK: Anthera ...

HAYWARD, Calif., April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today ...

SAN MATEO, Calif., Sept. 24 Anthera Pharmaceuticalsannounced today they have reached agreement with the U.S. Food and DrugAdministration (FDA) on a Phase 3 protocol for varespladib (A-002) in ...

HAYWARD, CA - March 4, 2010 - Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the ...

Anthera Pharmaceuticals, Inc.ANTH shares increased almost 11% on Jan 22 after the company announced encouraging results from the second interim futility analysis of a phase III study -- RESULT - on ...

HAYWARD, Calif., July 24, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 33,000,000 ...